NovaBridge Biosciences (NBP) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 18.2% versus a loss of 78.2%. Over five years, NRXP leads with a -97.4% price change compared with -98.1% for NBP. NovaBridge Biosciences is the larger company by market cap ($146.2 million vs $112.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | NRXP |
|---|---|---|
| Share price | $1.26 | $2.60 |
| Market cap | $146.16M | $112.57M |
| 1-day change | -2.33% | -4.06% |
| YTD return | -68.34% | -4.06% |
| 1-year return | -78.16% | -18.24% |
| 5-year return | -98.13% | -97.37% |
| EPS (TTM) | $-0.69 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.23M |
| Net income (latest FY) | $-46.27M | $-28.62M |
| Gross margin | — | 58.78% |
| Operating margin | — | -1324.41% |
| Net margin | — | -2336.49% |
| 52-week high | $5.97 | $5.06 |
| 52-week low | $1.26 | $1.62 |
| Distance from 52-week high | -78.89% | -48.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +614.29% | +1380.77% |
| Average volume | 390.05K | 860.32K |
| Shares outstanding | 116.00M | 43.30M |
| Employees | 30 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed NBP by 59.9 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
NBP vs NRXP FAQ
Which is bigger, NovaBridge Biosciences or NRX Pharmaceuticals?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $146.16M compared with $112.57M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, NBP or NRXP?
NRXP returned -18.24% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.